Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

ELIGIBILITY Inclusion: * ECOG Performance Score(PS) less than 2. * Must be at least 18 years of age and capable of giving informed consent. * Must be less than three years from the original diagnosis of Philadelphia chromosome positive CML in chronic phase. * Patient is not in cytogenetic remission. * No anticipation of bone marrow or stem cell transplant for six months unless these therapies are deemed necessary by a treatment physician due to the evolution of the disease; * Concurrent treatment with hydroxyurea or Gleevec is allowed.PAST treatment with IFN alpha, Ara-C or other cytoxic agents is allowed * Must not have any serious illness such that their medical condition might be compromised by participation in the study. * Must have adequate renal function (serum creatinine \< 2.0), hepatic function (bilirubin and transaminase less than 2.0 x of the upper normal limit). * Must not be on corticosteroid therapy, or other immunosuppressive medications. Exclusion * Patients with an ECOG Performance Score greater than or equal to 2. * Patient is greater than or equal to 3 years out from the original diagnosis. * Significant anemia (Hemoglobin \< 10 g/dl) and thrombocytopenia (platelet \< 20,000/ml) requiring transfusion. * Peripheral blast count is over 10%. * Positive urine or blood pregnancy test. * Impaired renal function (serum creatinine \> 2.0), hepatic function (bilirubin and transaminase more than 2.0 x of the upper normal limit). * Patient with significant active …